Correction to: Differential Expression of Axl and Correlation with Invasion and Multidrug Resistance in Cancer Cells (Cancer Investigation, (2012), 30, 4, (287-294), 10.3109/07357907.2012.657816);Differential expression of Axl and correlation with invasion and multidrug resistance in cancer cells

Cancer Investigation

Volumn 30, Issue 4, 2012, Pages 287-294

  Zhao, Yongfu ^a   Sun, Xiance ^a   Jiang, Lili ^a   Yang, Fengjuan ^b   Zhang, Zhaohai ^a   Jia, Li ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b Haining Senior High School   (China)

Author keywords

Axl; Breast cancer; Invasion; Leukemia; Multidrug resistance

Indexed keywords

DOXORUBICIN; PACLITAXEL; SMALL INTERFERING RNA; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AXL GENE; CANCER CELL; CANCER INVASION; CANCER THERAPY; CELL INVASION; CELL PROLIFERATION; CELL STRAIN K 562; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC CORRELATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RNA INTERFERENCE; TUMOR XENOGRAFT;

EID: 84860188906     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357907.2021.1915556     Document Type: Erratum

References (27)

1. Chan HS, Torner PS, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in sof tissue sarcoma of childhood. J Clin Oncol 1990;8:689-704. (Pubitemid 20127254)
2. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, Plagne R, Chassagne J. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991;83: 111-116.
3. Yang JM, Yang GY, Medina DJ, Vassil AD, Liao J, Hait WN. Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease. BBRC 1999;266:167-173. (Pubitemid 30028786)
4. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991;51:2720-2726.
5. Hafzi S, Dahlback B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev 2006;17:295-304. (Pubitemid 44038616)
6. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R 3rd, Le Beau MM, Earp HS, Liu ET. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 1991;11:5016-5031. (Pubitemid 21895263)
7. Rochlitz C, Lohri A, Bacchi M, Schmidt M, Nagel S, Fopp M, Fey MF, Herrmann R, Neubauer A. Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 1999;13:1352-1358. (Pubitemid 29429761)
8. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS, Wu CW. Expression of Axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 2005;7:1058-1064.
9. Chung BI, Malkowicz SB, Nguyen TB, Libertino JA, McGarvey TW. Expression of the proto-oncogene Axl in renal cell carcinoma. DNA Cell Biol 2003;22:533-540. (Pubitemid 37174752)
10. Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol 2005;204:36-44. (Pubitemid 40776804)
11. Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC. Expression profle of tyrosine kinases in breast cancer. Clin Cancer Res 2002;8:361-367. (Pubitemid 34193951)
12. Wu CW, Li AF, Chi CW, Lai CH, Huang CL, Lo SS, Lui WY, Lin WC. Clinical signifcance of Axl kinase family in gastric cancer. Anticancer Res 2002;22:1071-1078. (Pubitemid 34836153)
13. Holland SJ, Powell MJ, Franci C, Chan EW, Friera AM, Atchison RE, McLaughlin J, Swif SE, Pali ES, Yam G, Wong S, Lasaga J, Shen MR, Yu S, Xu W, Hitoshi Y, Bogenberger J, Nör JE, Payan DG, Lorens JB. Multiple roles for the receptor tyrosine kinase Axl in tumor formation. Cancer Res 2005;65:9294-9303. (Pubitemid 41507996)
14. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, Nagle R, Bearss D. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007;26:3909-3919. (Pubitemid 46884299)
15. Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, Lai GM, Chuang SE. Receptor tyrosine kinase Axl is induced by chemotherapy drugs and overexpression of Axl confers drug resistance in acute myeloid leukemia. Cancer Lett 2008;268:314-324.
16. Lay JD, HongCC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, Chuang SE. Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing Axl. Cancer Res 2007;67:588-599.
17. Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, Miller E, Smyth JF, Langdon SP. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res 2005;65:6789-6800. (Pubitemid 41060717)
18. Challier C, Uphof CC, Janssen JW, Drexler HG. Diferential expression of the Ufo/Axl oncogene in human leukemia-lymphoma cell lines. Leukemia 1996;10:781-787. (Pubitemid 26168394)
19. Krishna R, Mayer LD. Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators. Curr Med Chem Anti-Cancer Agents 2001;1:163-174.
20. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R. The molecular interaction of the high afnity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 1999;128:403-411. (Pubitemid 29458600)
21. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 2000;58:624-632.
22. Kerbel R, Korczak S, Lagarde BA. Growth dominance of the metastatic cancer cell: cellular and molecular aspects. Adv Cancer Res 1990;5:87-132. (Pubitemid 20259301)
23. Su ZZ, Austin VN, Zimmer SG, Fisher PB. Defning the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Haras-transformed cloned rat embryo fbroblast cells. Oncogene 1993;8:1211-1219. (Pubitemid 23129843)
24. Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM, Salzberg DB, Foreman NK, Liang X, Torburn A, Graham DK. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ter 2010;9:1298-1307.
25. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-370. (Pubitemid 38579482)
26. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of Axl. Cancer Res 2009;69:6871-6878.
27. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orf L, Szabadkai I, Daub H, Kéri G, Ullrich A. Axl is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 2008;68:1905-1915. (Pubitemid 351416577)